Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

The live and archived webcast for the Cantor event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: [email protected]

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: [email protected]

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Bright Minds Biosciences Inc. (DRUG)
• FLUENT Reports Second Quarter 2026 Results
• $100M Multicoin Bet Dominates Hyperliquid News as AlphaPepe’s Smaller-Cap Setup Pulls Risk-Hungry Buyers